Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Novavax to Present at the Ladenburg Thalmann 2017 Healthcare Conference
By: Nasdaq / GlobeNewswire - 19 Sep 2017Back to overview list

GAITHERSBURG, Md., Sept.  19, 2017  (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will present at the Ladenburg Thalmann 2017 Healthcare Conference.

Presentation details are as follows:
Date: Tuesday, September 26, 2017
Time: 11:00 - 11:25 am ET
Location: Track 5, Montmartre, Sofitel Hotel, New York City
Live webcast: www.novavax.com , "Investors"/"Events"

A replay of the presentation will also be accessible under the "Investors/Events" section of the Novavax website at novavax.com .

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com .

Contact:

Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor & Media Relations
ir@novavax.com
240-268-2000

Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Russo Partners, LLC
David Schull
Maggie Beller
david.schull@russopartnersllc.com
maggie.beller@russopartnersllc.com
212-845-4271




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novavax, Inc. via GlobeNewswire

HUG#2135426
Related companies:https://www.fiercepharma.com/marketing/novavax-hoping-bump-its-lagging-european-launch-asks-ema-authorize-its-covid-shot
Copyright 2017 Nasdaq / GlobeNewswire Back to overview list
to the top ↑